Correction to: Clinical Pharmacokinetics (2025) 64:53–66 https://doi.org/10.1007/s40262-024-01454-4 In the original version of this article, the given and family names of J. G. Coen van Hasselt were incorrectly structured as Coen J.G. van Hasselt. The correct name should read as given name: J. G. Coen and family name: van Hasselt.
N,N-Dimethyltryptamine (DMT) is currently being studied for its therapeutic potential in various psychiatric disorders. An understanding of its pharmacokinetics (PK) is essential to determine appropriate dose ranges in future clinical studies. We conducted a systematic literature review on the PK of DMT. Clinical studies that administered known amounts of DMT and reported PK data and/or...
Overall, we found the pharmacokinetic parameters of psilocin to be consistent between studies. This review may guide the further clinical development of psilocybin-based therapies.
BACKGROUND AND OBJECTIVE\nMETHODS\nRESULTS\nCONCLUSION\nN,N-Dimethyltryptamine (DMT) is currently being studied for its therapeutic potential in various psychiatric disorders. An understanding of its pharmacokinetics (PK) is essential to determine appropriate dose ranges in future clinical studies. We conducted a systematic literature review on the PK of DMT.\nClinical studies that administered...